Yeo Anne-Emmanuella, Hendrix Aurore, Confente Caterina, Christian Nicolas, Mansvelt Baudouin, Pairet Géraldine, Seront Emmanuel
Department of Medical Oncology, Jolimont Hospital, La Louvière, Belgium.
Department of Radiotherapy, Jolimont Hospital, La Louvière, Belgium.
Front Oncol. 2021 Nov 17;11:764758. doi: 10.3389/fonc.2021.764758. eCollection 2021.
Metastatic prostate cancer remains a challenge for clinicians. Metastases involve mainly the bone compartment and can manifest as oligometastatic disease. In this setting, the role of metastasis-directed therapies (MDT) including surgery and/or stereotactic body radiotherapy is currently evaluated. Visceral metastases are less common and have very poor prognosis in mPC. Whether treating isolated visceral metastases such as liver metastases with MDT could increase the prognosis remains unknown. We report the management of a prostate cancer patient who progressed on androgen deprivation therapy with apparition of two liver metastases. We describe the feasibility of combining MDT with abiraterone acetate and prednisone in a patient with metastatic castration-resistant prostate cancer. MDT allowed the interruption of abiraterone acetate, preventing cumulative toxicity of this agent.
转移性前列腺癌对临床医生来说仍是一项挑战。转移主要累及骨组织，可表现为寡转移疾病。在这种情况下，目前正在评估包括手术和/或立体定向体部放疗在内的转移导向治疗（MDT）的作用。内脏转移较少见，在转移性前列腺癌（mPC）中预后很差。用MDT治疗孤立的内脏转移如肝转移是否能改善预后仍不清楚。我们报告了一名前列腺癌患者的治疗情况，该患者在雄激素剥夺治疗过程中出现了两处肝转移并病情进展。我们描述了在一名转移性去势抵抗性前列腺癌患者中联合MDT与醋酸阿比特龙和泼尼松的可行性。MDT使得能够中断醋酸阿比特龙治疗，防止了该药物的累积毒性。
